WaveMan
WaveMan · Company
IDXX · Idexx Laboratories Inc /De
> Search tickers & screens ⌘K
LIVE
← All companies

IDXX Idexx Laboratories (IDXX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0000874716
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $298.8K priced

What the filings say about IDXX

Insiders, 180 days
-$1.2M net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2026-01-13
Planned sales (Form 144), 90 days
$1.2M
1 notice

Idexx Laboratories insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, IDEXX LABORATORIES INC /DE insiders sold a net $1.2M of stock across 221 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Kingsley Lawrence D
Director
SELL
2026-09-09 SECtraded 2026-09-04
2,203
$1.2M
+10.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 23.0% of the 9,568 shares held after it.
  • No other insider sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kingsley Lawrence D sold about $1.2M of IDXX on Sep 4, 2026; 3 funds added in the latest 13F quarter.
Hunt Nimrata
Executive Vice President
SELL
2026-03-05 SECtraded 2026-03-03
1,758
$1.1M
-7.9%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Feb 26, 2026.
  • The trade is 9.7% of the 18,140 shares held after it.
  • 4 other insiders sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice President Hunt Nimrata sold about $1.1M of IDXX on Mar 3, 2026; 4 other insiders sold within 30 days and 3 funds added in the latest 13F quarter.
MAZELSKY JONATHAN JAY
President and CEO
SELL
2026-03-02 SECtraded 2026-02-26
2,860
$1.9M
-11.8%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (36 sales), the last on Aug 6, 2025.
  • The trade is 3.0% of the 94,914 shares held after it.
  • 4 other insiders sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO MAZELSKY JONATHAN JAY sold about $1.9M of IDXX on Feb 26, 2026; 4 other insiders sold within 30 days and 3 funds added in the latest 13F quarter.
MAZELSKY JONATHAN JAY
President and CEO
SELL
2026-03-02 SECtraded 2026-02-26
1,095
$713.4K
-11.8%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (36 sales), the last on Aug 6, 2025.
  • The trade is 1.0% of the 104,556 shares held after it.
  • 4 other insiders sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO MAZELSKY JONATHAN JAY sold about $713.4K of IDXX on Feb 26, 2026; 4 other insiders sold within 30 days and 3 funds added in the latest 13F quarter.
MAZELSKY JONATHAN JAY
President and CEO
SELL
2026-03-02 SECtraded 2026-02-26
1,281
$833.5K
-11.8%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (36 sales), the last on Aug 6, 2025.
  • The trade is 1.2% of the 105,651 shares held after it.
  • 4 other insiders sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO MAZELSKY JONATHAN JAY sold about $833.5K of IDXX on Feb 26, 2026; 4 other insiders sold within 30 days and 3 funds added in the latest 13F quarter.
221 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 216 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.2M over 180 days
-$1.2M over 90 days
below 64% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
below 99% of Pharma & Biotech
Revenue
+10.4% year over year
more than 60% of Pharma & Biotech
Margin
24.6% net margin
more than 88% of Pharma & Biotech
Buybacks
$697.8M repurchased, FY to 2026-06-30
more than 88% of Pharma & Biotech
Short interest
2.5% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
below 63% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IDXX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-11.6%12M
-20%-7%+7%+21%2025-102025-122026-022026-042026-062026-082026-10 2025-11-07 · Hunt Nimrata sold $3.6M2026-02-26 · MAZELSKY JONATHAN JAY sold $2.4M2026-02-26 · MAZELSKY JONATHAN JAY sold $1.9M2026-02-26 · MAZELSKY JONATHAN JAY sold $1.9M2026-02-10 · FENNELL GEORGE sold $1.8M2026-02-10 · FENNELL GEORGE sold $1.8M2026-02-26 · Hunt Nimrata sold $1.8M2026-02-26 · MAZELSKY JONATHAN JAY sold $1.7M2026-02-17 · Erickson Michael G sold $1.7M2026-02-10 · FENNELL GEORGE sold $1.4M2026-09-04 · Kingsley Lawrence D sold $1.2M2026-03-03 · Hunt Nimrata sold $1.1M2026-02-26 · MAZELSKY JONATHAN JAY sold $1.1M2025-11-07 · Hunt Nimrata sold $1.0M2025-11-07 · Hunt Nimrata sold $1.0M2026-02-26 · MAZELSKY JONATHAN JAY sold $975.9K2025-11-07 · Hunt Nimrata sold $972.2K2026-02-26 · MAZELSKY JONATHAN JAY sold $882.1K2026-02-26 · MAZELSKY JONATHAN JAY sold $833.5K2026-02-17 · Erickson Michael G sold $806.6K2026-02-26 · MAZELSKY JONATHAN JAY sold $793.3K2026-02-26 · MAZELSKY JONATHAN JAY sold $765.5K2026-02-26 · MAZELSKY JONATHAN JAY sold $727.3K2026-02-10 · FENNELL GEORGE sold $726.6K2026-02-26 · MAZELSKY JONATHAN JAY sold $713.4K2026-02-10 · FENNELL GEORGE sold $686.0K2026-02-26 · MAZELSKY JONATHAN JAY sold $662.2K2026-02-10 · FENNELL GEORGE sold $626.7K2026-02-17 · Vandebroek Sophie V. sold $594.1K2026-02-17 · Erickson Michael G sold $433.4K2026-02-17 · Vandebroek Sophie V. sold $326.2K2026-02-17 · Erickson Michael G sold $284.4K2026-02-10 · FENNELL GEORGE sold $255.7K2026-02-17 · Erickson Michael G sold $127.5K2026-02-10 · FENNELL GEORGE sold $26.0K2026-02-17 · Erickson Michael G sold $25.2K2026-09-04 · LAWRENCE D KINGSLEY filed to sell $1.2M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IDXX: institutional holders (13F)

13F holdings, latest reported quarter
CAPITAL COUNSEL LLC/NY
419,151 sh
$220.7M
DF DENT & CO INC
39,515 sh
$20.8M
ACADEMY CAPITAL MANAGEMENT
34,801 sh
$18.3M
FRANKLIN STREET ADVISORS INC /NC
26,215 sh
$13.8M
Azimuth Capital Investment Management LLC
18,111 sh
$9.5M

Congress trades in IDXX

STOCK Act disclosures, US House only, filed up to 45 days after the trade
April McClain Delaney
Sold 2026-01-13 · disclosed 20 days later
$1,001 - $15,000
April McClain Delaney
Sold 2025-10-16 · disclosed 19 days later
$1,001 - $15,000
Byron Donalds
Bought 2025-09-04 · disclosed 33 days later
$1,001 - $15,000
April McClain Delaney
Sold 2025-08-07 · disclosed 26 days later
$1,001 - $15,000
April McClain Delaney
Sold 2025-07-09 · disclosed 27 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IDXX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
LAWRENCE D KINGSLEY
Filed 2026-09-04
$1.2M
Executive pay vs shareholder return · Jonathan J. Mazelsky
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$14.6M
$31.8M
$3.1M
+35%
+48%
2024
$13.0M
$2.3M
$3.8M
-17%
+29%
2023
$11.5M
$22.7M
$3.3M
+11%
+26%
2022
$9.8M
-$13.8M
$2.8M
-18%
+24%
2021
$9.1M
$28.2M
$2.8M
+32%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.2M sold by insiders over 180 days, 3 funds added last quarter, $1.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IDXX financials

Revenue growth
+10.4%
XBRL, annual
Net margin
24.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.6B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+25.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$1.3B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.28x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
3.05x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+74.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+33.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+64.7%
operating income after a 20.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+68.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
39.38x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$44.4B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+2.8%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
2.13x
P/E over trailing EPS growth of 18%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$4.3B$3.9B$3.7B$3.4B
Gross profit$2.7B$2.4B$2.2B$2.0B
Operating income$1.4B$1.1B$1.1B$898.8M
Net income$1.1B$887.9M$845.0M$679.1M
EPS (diluted)13.0810.6710.068.03
Operating cash flow$1.2B$929.0M$906.5M$543.0M
Cash$180.1M$288.3M$453.9M$112.5M
Long-term debt$374.8M$449.8M$622.9M$694.4M
Buybacks$1.2B$837.0M$71.9M$819.7M
SEC XBRL, fiscal years, as known on 2026-10-27

IDXX Stock Sonar score 6/7 axes

Find similar shapesCompare

IDXX ranks highest on profitability (95th percentile) and financial health (68th), and lowest on institutional and government (6th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
95
Inputs
  • Return on equity+74.2% · 96 pct, sector of 545
  • Return on assets+33.7% · 94 pct, sector of 691
  • Return on invested capital+64.7% · 91 pct, sector of 45
  • Return on capital employed+68.5% · 99 pct, sector of 576
Financial health
68
Inputs
  • Debt to equity0.28x · 40 pct, sector of 352
  • Cash flow to debt3.05x · 95 pct, sector of 371
Growth
60
Inputs
  • Revenue growth, YoY+10.4% · 60 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
17
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.2M · 33 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
6
Inputs
  • Funds adding, latest quarter3 · 1 pct, sector of 698
  • Congress net buyers, 365d-1 · 10 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
53
Inputs
  • Short interest, % of float+2.5% · 70 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+13.2% · 36 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IDXX filings, in plain words

Are Idexx Laboratories insiders buying or selling IDXX?

In the 180 days to 2026-10-27, Idexx Laboratories insiders were net sellers, a net $1.2M across purchases and sales reported on Form 4, by 1 seller.

Have members of Congress traded IDXX?

Yes. In the year to 2026-10-27, 0 House members disclosed buying IDXX and 1 House member disclosed selling it; the latest on record is a sale by April McClain Delaney dated 2026-01-13.

Are there planned insider sales of IDXX?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $1.2M of stock; the latest, by LAWRENCE D KINGSLEY, was filed 2026-09-04.

Read the full summary

In the 180 days to 2026-10-27, Idexx Laboratories insiders were net sellers of IDXX, a net $1.2M across purchases and sales reported on Form 4 by 1 seller. In the year to 2026-10-27, 0 members of Congress disclosed buying IDXX and 1 member disclosed selling it; the latest on record is a sale by April McClain Delaney dated 2026-01-13. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $1.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies